The first European study on myopia management treatment combining DIMS spectacle lenses and low-dose atropine

The study, designed and carried out by Prof. Paolo Nucci and his team, composed of Dr. Andrea Lembo and Dr. Irene Schiavetti, in collaboration with Rakhee Shah, David Edgar, and Bruce Evans, was conducted with the aim of evaluating the effectiveness of spectacle lenses with D.I.M.S. Technology in slowing down the progression of myopia in a population of young Europeans.


It is an observational non-randomized study on young patients aged between 6 and 18 years with progressive myopia in their developmental age, without any other associated ocular pathologies. Participants were prescribed either 0.01% atropine eye drops, MiYOSMART spectacle lenses with D.I.M.S. Technology, or a combined treatment of "atropine + DIMS spectacle lenses," based on the child/parent's choice. The myopia progression in these three treatmeant groups was then compared with a group of patients wearing conventional single vision lenses (control group). Subjective visual acuity, cycloplegic spherical equivalent refraction (SER), and axial length (AL) were evaluated at 3, 6, and 12 months from the start of the treatment.


Preliminary results were presented in September 2022 at the International Myopia Conference 2022 in Rotterdam, the analysis conducted on the 146 enrolled patients revealed a reduction in myopia progression in the three treatment groups, both from the SER and AL perspectives, as well as in the subjective worsening of visual acuity. These results confirm the efficacy of diluted atropine and DIMS spectacle lenses in slowing down the myopia progression on their own. The effectiveness of both treatments increases further when prescribed in combination, revealing an even more significant reduction in myopia progression than the other treatment groups.



“Although the non-randomization of the four treatment groups could be seen as a weakness, it actually represents a strength, as it more closely mimics real-life, allowing the child/parents to select the treatment option they prefer." explains Dr. Andrea Lembo "We are extremely proud to reveal the first European study on the efficacy of MiYOSMART spectacle lenses in the Caucasian population: a wonderful teamwork that confirms the efficacy of DIMS spectacle lenses in slowing down the progression of myopia in European children."

Dr. Andrea Lembo

University Hospital San Giuseppe Multimedica in Milan, Italy

To read the official publication, please visit

Learn More About MiYOSMART